Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRC Post-surgical Assessment and Recurrence Monitoring

ABSTRACT: The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2258330 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

Project description:This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.

| 2403134 | ecrin-mdr-crc

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring

Project description:A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring

| PRJNA390898 | ENA

Microfluidic platform for monitoring Saccharomyces cerevisiae mutation accumulation assay

Project description:Microfluidic platform for monitoring Saccharomyces cerevisiae mutation accumulation assay

| PRJEB43850 | ENA

Urine Cell-Free RNA versus Plasma Cell-Free RNA for Monitoring of Immune and Urinary Tract Complications

Project description:While it is well known that cell-free RNA (cfRNA) can be isolated from urine, the diagnostic potential of this urine cfRNA, especially in comparison to plasma cfRNA, remains underexplored. Here, we directly compared the utility of urine cfRNA and plasma cfRNA for the monitoring of systemic and urinary tract related complications. We analyzed 272 matched plasma and urine cfRNA isolates obtained from three cohorts of patients: Hematopoietic Stem Cell Transplant (HSCT) recipients, patients with acute kidney injury (AKI), and healthy volunteers. The data highlight the unique cellular origins and properties of urinary and plasma RNA. Most importantly, we find that although plasma cfRNA is a superior analyte for monitoring immune and systemic complications, urinary cfRNA is more sensitive to complications of the urinary tract, including cell-type specific injury in the kidney. These findings highlight the potential of urine cfRNA as a novel analyte in diagnostic medicine.

2025-03-06 | GSE261018 | GEO

Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer

Project description:This study dynamically monitored the prognosis of stage I-IV colorectal cancer patients who could receive radical surgical resection by detecting the levels of polygene methylation in plasma samples from patients with colorectal cancer. In patients with colorectal cancer feasible radical surgery, plasma ctDNA methylation detection was performed before and after surgical treatment and during regular follow-up to explore the predictive effect of plasma ctDNA methylation status at different time points on postoperative recurrence. To explore whether postoperative dynamic monitoring of plasma ctDNA methylation can be used for adjuvant chemotherapy efficacy evaluation and whether it can indicate tumor recurrence and metastasis earlier than imaging examination.

| 2739915 | ecrin-mdr-crc

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring

Project description:Development of a cost-effective and practical targeted transcriptional fingerprinting assay (TFA) for monitoring a diverse repertoire of immune responses identified in the human blood transcriptome relying on a modular transcriptional repertoire built on the basis of variations in transcript abundance measured on a genome wide scale in the blood of nearly 1000 subjects across 16 immunologic conditions.

2020-06-16 | GSE100150 | GEO

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring (TB Datasets)

2020-06-16 | GSE100166 | GEO

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring (Staph Datasets)

2020-06-16 | GSE100165 | GEO

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring (SoJIA Datasets)

2020-06-16 | GSE100164 | GEO

A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring (SLE Datasets)

2020-06-16 | GSE100163 | GEO